High-dose alpha-tocopherol therapy does not affect HDL subfractions in patients with coronary artery disease on statin therapy.

High-dose alpha-tocopherol therapy does not affect HDL subfractions in patients with coronary artery disease on statin therapy. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

High-dose alpha-tocopherol therapy does not affect HDL subfractions in patients with coronary artery disease on statin therapy. Abstract Text:

Uma Singh,James Otvos,Amitava Dasgupta,James A de Lemos,Sridevi Devaraj,Ishwarlal Jialal,

BACKGROUND: Subfractions of HDL, particularly large HDL (HDL2), are inversely correlated with the severity of coronary artery disease (CAD). alpha-Tocopherol (AT) is the main lipid-soluble antioxidant in plasma. Results of a previous small study (n = 44) suggested that either a combination of an antioxidant cocktail [800 IU/day 2R,4'R,8'R-(RRR)-AT plus 1 g vitamin C, 25 mg beta-carotene, and 100 microg selenium] or individual antioxidant vitamins combined with simvastatin-niacin (S-N) therapy attenuated the protective increase in HDL2 seen with S-N alone. Few data are available on the effect of AT therapy alone on HDL subfractions, which we addressed in this study. METHODS: In a prospective placebo-controlled study, we randomized 127 patients with stable CAD to receive high-dose RRR-AT (1200 IU/day for 2 years) or placebo. HDL subfractions (small, medium, and large HDL particles) were analyzed by nuclear magnetic resonance spectroscopy. RESULTS: AT concentrations significantly increased in the AT arm but not with placebo. No differences were noted between AT and placebo groups in concentrations of total cholesterol, triglyceride, LDL-cholesterol, or HDL-cholesterol. AT therapy did not affect total, small, medium, or large HDL particles compared with baseline or placebo. Furthermore, serum apolipoprotein A1 concentrations did not change after 2 years AT therapy as compared with baseline. CONCLUSIONS: High-dose AT therapy administered for a 2-year period does not negatively affect either HDL subfractions or apolipoprotein A1 in patients with CAD on statin therapy. Thus the negative interaction previously proposed between antioxidant cocktail and statin therapy cannot be attributed to AT.

High-dose alpha-tocopherol therapy does not affect HDL subfractions in patients with coronary artery disease on statin therapy. Publishing Authors By Initials

U Singh,J Otvos,A Dasgupta,JA de Lemos,S Devaraj,I Jialal,

For similar chemical actions and uses: pharmacologic actions: physiological effects of drugs: growth substances: micronutrients: vitamins research abstracts see: chemical actions and uses: pharmacologic actions: physiological effects of drugs: growth substances: micronutrients: vitamins research

PUBMED ID PMID:

MEDLINE DATE:

High-dose alpha-tocopherol therapy does not affect HDL subfractions in patients with coronary artery disease on statin therapy. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: Clinical chemistry

VOLUME: 53

Page Numbers: 525-8

Journal Abbreviation: Clin. Chem.

ISSN: 0009-9147

DAY: 18

MONTH: 01

YEAR: 2007

High-dose alpha-tocopherol therapy does not affect HDL subfractions in patients with coronary artery disease on statin therapy. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9421549

High-dose alpha-tocopherol therapy does not affect HDL subfractions in patients with coronary artery disease on statin therapy. Keywords Mesh Terms:

KEYWORDS: Vitamins

MESH TERMS: therapeutic use

Chemical & Substance for Abstract: High-dose alpha-tocopherol therapy does not affect HDL subfractions in patients with coronary artery disease on statin therapy. Information

Substance Name: Tocopherols

Registry Number: 1406-66-2

Grant and Affiliation Information for High-dose alpha-tocopherol therapy does not affect HDL subfractions in patients with coronary artery disease on statin therapy.

AFFILIATION: University of California Davis Medical Center, Sacramento, California 95817, USA.

Country: United States

AGENCY: United States NCCAM

GRANT: R01 AT 00005

ACRONYM: AT

MEDLINETA: Clin Chem

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

High-dose alpha-tocopherol therapy does not affect HDL subfractions in patients with coronary artery disease on statin therapy Related Publications

• A dose-response study on the effects of purified lycopene supplementation on biomarkers of oxidative stress.
• Adiponectin decreases C-reactive protein synthesis and secretion from endothelial cells: evidence for an adipose tissue-vascular loop.
• C-reactive protein decreases endothelial nitric oxide synthase activity via uncoupling.
• CRP and adiponectin and its oligomers in the metabolic syndrome: evaluation of new laboratory-based biomarkers.
• Contemporary scientific insights: role of biomarkers of inflammation in cardiovascular disease/atherosclerosis.
• Detection by immunofixation of M proteins in hypogammaglobulinemic patients with normal serum protein electrophoresis results.
• Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome.
• Editor's Perspective on Metabolic Syndrome for 2008.
• Editorial.
• Effect of high-dose {alpha}-tocopherol supplementation on biomarkers of oxidative stress and inflammation and carotid atherosclerosis in patients with coronary artery disease.
• Gamma-tocopherol supplementation alone and in combination with alpha-tocopherol alters biomarkers of oxidative stress and inflammation in subjects with metabolic syndrome.
• High-dose alpha-tocopherol therapy does not affect HDL subfractions in patients with coronary artery disease on statin therapy.
• High-fat, energy-dense, fast-food-style breakfast results in an increase in oxidative stress in metabolic syndrome.
• Human C-reactive protein promotes oxidized low density lipoprotein uptake and matrix metalloproteinase-9 release in Wistar rats.
• Increased Toll-Like Receptor (TLR) 2 and TLR4 Expression in Monocytes from Patients with Type 1 Diabetes: Further Evidence of a Proinflammatory State.
• Oxidative stress and atherosclerosis.
• RRR-alpha-tocopheryl acetate supplementation at pharmacologic doses decreases low-density-lipoprotein oxidative susceptibility but not protein glycation in patients with diabetes mellitus.
• Simvastatin (40 mg/day), adiponectin levels, and insulin sensitivity in subjects with the metabolic syndrome.
• Simvastatin reduces circulating plasminogen activator inhibitor 1 activity in volunteers with the metabolic syndrome.
• Statins and biomarkers of inflammation.
• The biological effects of CRP are not attributable to endotoxin contamination: evidence from TLR4 knockdown human aortic endothelial cells.
• The effect of weight loss and dietary fatty acids on inflammation.
• Validation of the circulating monocyte being representative of the cholesterol-loaded macrophage: biomediator activity.